Drug Discovery

Pfizer acquires Amplyx Pharmaceuticals

Pharmaceutical company Pfizer has acquired a privately held company Amplyx Pharmaceuticals for an undisclosed amount.

Vertex and Obsidian partner to discover gene-editing medicines

Vertex Pharmaceuticals and Obsidian Therapeutics have established a multi-year collaboration for the discovery of new treatments that regulate gene editing.

AB Science and University of Chicago to conduct Covid-19 treatment research

French pharmaceutical company AB Science has signed an exclusive licensing agreement with the University of Chicago to conduct research for the prevention and treatment of Covid-19 with masitinib and its other proprietary drugs.

Amgen agrees to acquire biopharmaceutical company Rodeo Therapeutics

Biotechnology company Amgen has agreed to acquire privately held biopharmaceutical company Rodeo Therapeutics.

NIAID grants $2.5m to 12 institutes for bacteriophage therapy research

A branch of the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID) has granted $2.5m to 12 institutes across the world for bacteriophage therapy research.

Bharat Biotech’s Phase III interim results of COVAXIN demonstrate efficacy of 81%

Biopharmaceutical company Ocugen has announced that its co-development partner, Bharat Biotech, announced the results of the first interim analysis of its Phase 3 study of COVAXIN, which is a whole virion inactivated Covid vaccine candidate.

Boehringer Ingelheim, Gubra to validate new Peptides for obesity

Boehringer Ingelheim has entered into a new research and licensing agreement with biotech company Gubra to identify and validate innovative peptides to treat obesity.

Merck signs agreement to purchase Pandion Therapeutics

World’s leading biopharmaceutical firm Merck has announced that it has entered into a definitive agreement to purchase Pandion Therapeutics through a subsidiary, for a total equity value of about $1.85m.

UCB expands partnership with Microsoft to speed up drug development

Belgium-based biopharmaceutical firm UCB has expanded its collaboration with technology company Microsoft to accelerate discovery and development of drugs for people living with severe diseases in immunology and neurology.